RAPT Therapeutics to report phase 2 trial data for urticaria drug
PositiveFinancial Markets

RAPT Therapeutics is set to unveil the results of its phase 2 trial for a new drug aimed at treating urticaria, a condition that causes hives and can significantly impact quality of life. This announcement is crucial as it could pave the way for new treatment options for patients suffering from this chronic condition, potentially improving their daily lives and offering hope for better management of symptoms.
— Curated by the World Pulse Now AI Editorial System